Developer docs
API playgroundTry for free, no card

Search company profiles

TRIMTECH Therapeutics

Full company profile

uuid0000dmu

Namestring
TRIMTECH Therapeutics
Legal namestring
TRIMTECH Therapeutics Ltd.
Company typeenum
Private
Founded yearint
2023
Descriptiontext

TRIMTECH Therapeutics Ltd. is a Cambridge, UK-based biotechnology company founded in 2023 that develops small molecule targeted protein degraders for neurodegenerative and inflammatory diseases. The company's proprietary platform exploits TRIM21, an underexploited E3 ubiquitin ligase, to selectively degrade disease-causing protein aggregates (such as tau oligomers and fibrils in Alzheimer's, Parkinson's, and Huntington's disease) while preserving functional monomeric proteins. Two complementary modalities sit on this platform: TRIMTAC®, bispecific chimeric degraders that recruit TRIM21 to aggregated targets, and TRIMGLUE®, molecular glue degraders that exploit cryptic mutual binding interactions and can address targets lacking known ligands.

The company's intellectual property is anchored in 20+ years of academic research by co-founders Leo James (MRC Laboratory of Molecular Biology) and Will McEwan (UK Dementia Research Institute, University of Cambridge), supported by peer-reviewed publications in Science, Cell, and PNAS. The leadership team combines these founders with experienced biotech operators: CEO Nicki Thompson (formerly founding CEO of Amphista Therapeutics, ~$150M raised, $2.3Bn in pharma deals) and Chair Alison Lawton (former CEO of Kaleido Biosciences who led its IPO). The SAB is chaired by Prof. Alessio Ciulli (FRS), a foundational figure in targeted protein degradation.

TRIMTECH is a pre-revenue, preclinical-stage company with no commercialized products and 1–10 employees. Its go-to-market motion follows the standard biotech partnering model: advance compounds through preclinical and IND-enabling stages internally and either license or co-develop with larger pharmaceutical partners. The company has raised $47M in seed funding across two tranches (March 2025: $31M led by Cambridge Innovation Capital and SV Health Investors' Dementia Discovery Fund; June 2026: $14M extension led by Johnson & Johnson Innovation – JJDC and BGF), with strategic pharma investors including Pfizer Ventures, M Ventures, and Eli Lilly taking board seats.

Short descriptiontext

TRIMTECH Therapeutics is a Cambridge, UK-based preclinical biotech developing TRIM21-based small molecule targeted protein degraders (TRIMTAC® and TRIMGLUE®) to selectively eliminate toxic protein aggregates causing neurodegenerative and inflammatory diseases. Founded in 2023 with $47M seed funding and pharma backing from J&J, Pfizer, and Eli Lilly.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
targeted protein degradation, small molecule therapeutics, neurodegenerative disease drug discovery, CNS-penetrant degraders, TRIM21 E3 ligase platform
Industry1 code
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Neurodegenerative Disease Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Therapeutic Development and Commercialization
TypeOne Time License
Description

Pre-revenue biotech company developing small molecule drugs for neurodegenerative diseases. Revenue will likely come from product sales following regulatory approval, or through licensing/partnership deals with pharmaceutical companies during development.

trimtechtherapeutics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

TRIMTECH Therapeutics develops novel small molecule targeted protein degraders (TRIMTAC® and TRIMGLUE®) that leverage the TRIM21 E3 ubiquitin ligase to selectively degrade disease-causing protein aggregates in the brain. The company is building a pipeline of CNS-penetrant therapeutics targeting neurodegenerative and inflammatory disorders such as Alzheimer's, Parkinson's, and Huntington's disease.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Demonstrated degradation of pathological tau aggregates and oligomers in preclinical models while preserving functional monomeric tau
+2 more records
Product overview1 text field

TRIMTECH Therapeutics is developing a differentiated portfolio of potent, highly specific small molecule targeted protein degraders for the treatment of neurodegenerative and inflammatory diseases. The company's proprietary platforms consist of TRIMTAC® (bispecific heterobifunctional degraders) and TRIMGLUE® (molecular glue degraders), both leveraging the unique mechanism of TRIM21 E3 ligase to selectively degrade toxic protein aggregates while preserving functional monomeric proteins. These two platforms work together to address protein aggregation disorders affecting the CNS and inflammatory conditions.

Product and service2 records
1TRIMTAC® Degraders
CategoryTargeted Protein Degradation Platform
Description

Bispecific 'chimeric' small molecule degraders that recruit the TRIM21 E3 ligase to disease-causing aggregated protein targets for selective degradation via the ubiquitin-proteasome system, while preserving functional monomeric proteins.

2TRIMGLUE® Degraders
CategoryTargeted Protein Degradation Platform
Description

Small molecule molecular glue degraders that exploit cryptic mutual binding interactions to bring protein targets and TRIM21 together, applicable where no suitable ligands are known for the target, enabling degradation of previously intractable protein aggregates.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-02-24
Description

Real estate partner at Babraham Research Campus. BioMed Realty completed lease-up of newest laboratory building with TRIMTECH and Tagomics signing leases for fully fitted laboratory and office space.

2Babraham Research Campus Ltd
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-02-24
Description

Landlord and research campus operator providing laboratory and office facilities to TRIMTECH as tenant. Supports early-stage and scaling life science companies within one of Europe's most established research ecosystems.

pharmiweb.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TRIMTECH Therapeutics

Neurodegenerative Disease Therapeuticstrimtechtherapeutics.com

TRIMTECH Therapeutics is a Cambridge, UK-based preclinical biotech developing TRIM21-based small molecule targeted protein degraders (TRIMTAC® and TRIMGLUE®) to selectively eliminate toxic protein aggregates causing neurodegenerative and inflammatory diseases. Founded in 2023 with $47M seed funding and pharma backing from J&J, Pfizer, and Eli Lilly.

What TRIMTECH Therapeutics does

TRIMTECH Therapeutics Ltd. is a Cambridge, UK-based biotechnology company founded in 2023 that develops small molecule targeted protein degraders for neurodegenerative and inflammatory diseases. The company's proprietary platform exploits TRIM21, an underexploited E3 ubiquitin ligase, to selectively degrade disease-causing protein aggregates (such as tau oligomers and fibrils in Alzheimer's, Parkinson's, and Huntington's disease) while preserving functional monomeric proteins. Two complementary modalities sit on this platform: TRIMTAC®, bispecific chimeric degraders that recruit TRIM21 to aggregated targets, and TRIMGLUE®, molecular glue degraders that exploit cryptic mutual binding interactions and can address targets lacking known ligands.

The company's intellectual property is anchored in 20+ years of academic research by co-founders Leo James (MRC Laboratory of Molecular Biology) and Will McEwan (UK Dementia Research Institute, University of Cambridge), supported by peer-reviewed publications in Science, Cell, and PNAS. The leadership team combines these founders with experienced biotech operators: CEO Nicki Thompson (formerly founding CEO of Amphista Therapeutics, ~$150M raised, $2.3Bn in pharma deals) and Chair Alison Lawton (former CEO of Kaleido Biosciences who led its IPO). The SAB is chaired by Prof. Alessio Ciulli (FRS), a foundational figure in targeted protein degradation.

TRIMTECH is a pre-revenue, preclinical-stage company with no commercialized products and 1–10 employees. Its go-to-market motion follows the standard biotech partnering model: advance compounds through preclinical and IND-enabling stages internally and either license or co-develop with larger pharmaceutical partners. The company has raised $47M in seed funding across two tranches (March 2025: $31M led by Cambridge Innovation Capital and SV Health Investors' Dementia Discovery Fund; June 2026: $14M extension led by Johnson & Johnson Innovation – JJDC and BGF), with strategic pharma investors including Pfizer Ventures, M Ventures, and Eli Lilly taking board seats.

TRIMTECH Therapeutics firmographics

Firmographics
Name
TRIMTECH Therapeutics
Legal name
TRIMTECH Therapeutics Ltd.
Website
https://trimtechtherapeutics.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
TRIMTECH Therapeutics is a Cambridge, UK-based preclinical biotech developing TRIM21-based small molecule targeted protein degraders (TRIMTAC® and TRIMGLUE®) to selectively eliminate toxic protein aggregates causing neurodegenerative and inflammatory diseases. Founded in 2023 with $47M seed funding and pharma backing from J&J, Pfizer, and Eli Lilly.
Ownership category
akta.pro rank

TRIMTECH Therapeutics industry classification

Industry
Product category
Neurodegenerative Disease Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Targeted protein degradation
  • Small molecule therapeutics
  • Neurodegenerative disease drug discovery
  • CNS-penetrant degraders
  • TRIM21 E3 ligase platform

Where TRIMTECH Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

TRIMTECH Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Therapeutic Development and Commercialization: Pre-revenue biotech company developing small molecule drugs for neurodegenerative diseases. Revenue will likely come from product sales following regulatory approval, or through licensing/partnership deals with pharmaceutical companies during development.

Go-to-market motion1 record

Marketing channels6 records

TRIMTECH Therapeutics product offering

Product offering

Core offering

TRIMTECH Therapeutics develops novel small molecule targeted protein degraders (TRIMTAC® and TRIMGLUE®) that leverage the TRIM21 E3 ubiquitin ligase to selectively degrade disease-causing protein aggregates in the brain. The company is building a pipeline of CNS-penetrant therapeutics targeting neurodegenerative and inflammatory disorders such as Alzheimer's, Parkinson's, and Huntington's disease.

Product overview

TRIMTECH Therapeutics is developing a differentiated portfolio of potent, highly specific small molecule targeted protein degraders for the treatment of neurodegenerative and inflammatory diseases. The company's proprietary platforms consist of TRIMTAC® (bispecific heterobifunctional degraders) and TRIMGLUE® (molecular glue degraders), both leveraging the unique mechanism of TRIM21 E3 ligase to selectively degrade toxic protein aggregates while preserving functional monomeric proteins. These two platforms work together to address protein aggregation disorders affecting the CNS and inflammatory conditions.

Differentiator

Problem solved

Functional benefit

Products and services

  • TRIMTAC® Degraders Bispecific 'chimeric' small molecule degraders that recruit the TRIM21 E3 ligase to disease-causing aggregated protein targets for selective degradation via the ubiquitin-proteasome system, while preserving functional monomeric proteins.
  • TRIMGLUE® Degraders Small molecule molecular glue degraders that exploit cryptic mutual binding interactions to bring protein targets and TRIM21 together, applicable where no suitable ligands are known for the target, enabling degradation of previously intractable protein aggregates.

Quantifiable outcome

  • Demonstrated degradation of pathological tau aggregates and oligomers in preclinical models while preserving functional monomeric tau
  • +2 more outcomes

Companies that use TRIMTECH Therapeutics

Customer profile

Segments1 record

Ideal customer profiles2 records

TRIMTECH Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

TRIMTECH Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor.

  • BioMed RealtyminorStrategic or Co-development Partner · 24 February 2026Real estate partner at Babraham Research Campus. BioMed Realty completed lease-up of newest laboratory building with TRIMTECH and Tagomics signing leases for fully fitted laboratory and office space.
  • Babraham Research Campus LtdminorStrategic or Co-development Partner · 24 February 2026Landlord and research campus operator providing laboratory and office facilities to TRIMTECH as tenant. Supports early-stage and scaling life science companies within one of Europe's most established research ecosystems.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

TRIMTECH Therapeutics competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

TRIMTECH Therapeutics social profiles

Digital presence

TRIMTECH Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TRIMTECH Therapeutics leadership team

Management profile

Number of profiles

Profiles9 records

TRIMTECH Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TRIMTECH Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TRIMTECH Therapeutics

What does TRIMTECH Therapeutics do?

TRIMTECH Therapeutics develops novel small molecule targeted protein degraders (TRIMTAC® and TRIMGLUE®) that leverage the TRIM21 E3 ubiquitin ligase to selectively degrade disease-causing protein aggregates in the brain. The company is building a pipeline of CNS-penetrant therapeutics targeting neurodegenerative and inflammatory disorders such as Alzheimer's, Parkinson's, and Huntington's disease.

Is TRIMTECH Therapeutics a public or private company?

TRIMTECH Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was TRIMTECH Therapeutics founded?

TRIMTECH Therapeutics was founded in 2023. It employs 11 to 50 people.

Where is TRIMTECH Therapeutics based?

TRIMTECH Therapeutics is headquartered in Cambridge, United States, in the North America region.

How does TRIMTECH Therapeutics make money?

One revenue line is on record: therapeutic Development and Commercialization.

Does TRIMTECH Therapeutics have an API?

No public API is recorded for TRIMTECH Therapeutics.

What industry is TRIMTECH Therapeutics in?

TRIMTECH Therapeutics's product category is Neurodegenerative Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyTrimtech, Biogen collaborate on small-molecule degradersTrimtech and Biogen signed a strategic research, option, and license agreement to develop small-molecule protein degraders for neurodegenerative diseases. The collaboration is based in Cambridge, England. No further details on the agreement's terms or progress were disclosed.News-MedicalTRIMTECH Therapeutics enters strategic research collaboration with Biogen to advance small molecule degraders for neurodegenerative diseaseTRIMTECH Therapeutics entered a strategic research collaboration with Biogen to develop small molecule protein degraders for neurodegenerative diseases. Biogen will receive a global exclusive license upon option exercise, with TRIMTECH eligible for up to $32 million upfront and research milestone payments, plus royalties.Business Wire BlogTRIMTECH Therapeutics Enters Strategic Research Collaboration With Biogen to Advance Small Molecule Degraders for Neurodegenerative DiseaseTRIMTECH Therapeutics entered a strategic research collaboration with Biogen to develop small molecule protein degraders for neurodegenerative diseases. The agreement includes up to $32 million in upfront and milestone payments, with total potential payments of up to $411 million plus royalties. Biogen will receive an exclusive global license upon option exercise.FinancialContent Business PageTRIMTECH Therapeutics Enters Strategic Research Collaboration With Biogen to Advance Small Molecule Degraders for Neurodegenerative DiseaseTRIMTECH Therapeutics entered a strategic research collaboration with Biogen to develop small molecule degraders for neurodegenerative diseases. The agreement includes up to $32 million in upfront and milestone payments, with total potential payments of up to $411 million plus royalties. Biogen will receive an exclusive license upon option exercise.StartupmafiaTRIMTECH Therapeutics Raises Total €41M Seed Round to Advance Neurodegenerative Disease TreatmentsTRIMTECH Therapeutics raised €12 million in seed funding, bringing its total seed round to €41 million. The extension was led by Johnson & Johnson Innovation and BGF, who will join the board. The company will use the capital to advance its protein-degradation therapies for neurodegenerative diseases.BusinessCloudTRIMTECH Therapeutics seed round tops £35mTRIMTECH Therapeutics raised a seed round exceeding £35 million, led by Johnson & Johnson Innovation and BGF. The Cambridge biotech develops small molecule therapies targeting protein aggregates in neurodegenerative diseases. The funding will support development of CNS-penetrant degraders for conditions like Alzheimer's.Pulse 2.0TRIMTECH Therapeutics Raises $47 Million Seed Funding To Advance Targeted Protein Degradation PortfolioTRIMTECH Therapeutics announced an additional $14 million in seed funding, bringing the total round to $47 million, led by Johnson & Johnson Innovation – JJDC and BGF. The biotechnology company is developing small-molecule therapies targeting protein aggregates associated with neurodegenerative diseases using its proprietary TRIMTAC and TRIMGLUE degrader platforms. Representatives from JJDC and BGF will join TRIMTECH's Board as non-executive directors following the seed extension.Longevity.TechnologyTrimTech adds $14m in funding to accelerate neurodegenerative disease treatmentsTrimTech Therapeutics announced an additional $14 million in seed funding, bringing its total seed round to $47 million (£35 million). The round was co-led by Johnson & Johnson Innovation, JJDC, Inc., and BGF, with participation from existing investors including Pfizer Ventures and Eli Lilly and Company. The company will use the proceeds to advance its TRIMTAC and TRIMGLUE targeted protein degradation platforms for developing CNS-penetrant degraders targeting neurodegenerative diseases.BdailyBiotech 'forges ahead' with £38 million funding boostCambridge-based biotech company TRIMTECH Therapeutics has secured an additional $14 million (£10.4 million) in seed funding, bringing its total seed round to $47 million (£35 million), to accelerate development of treatments for neurodegenerative diseases. The investment was led by Johnson & Johnson Innovation – JJDC and BGF, with representatives from both firms joining TRIMTECH's board as non-executive directors. The funding will support advancement of the company's TRIMTAC and TRIMGLUE platforms, which are designed to target and degrade harmful protein aggregates linked to conditions such as Alzheimer's disease.EU-StartupsCambridge’s TRIMTECH Therapeutics brings Seed round to €41 million for neurodegenerative disease workTRIMTECH Therapeutics, a Cambridge-based biotech company founded in 2023, has raised an additional €12 million in Seed extension funding, bringing its total Seed round to €41 million, to progress its small molecule therapies targeting protein aggregates associated with neurodegenerative diseases. The financing was co-led by Johnson & Johnson Innovation – JJDC and BGF, with both investors joining the company's board as non-executive directors. The funding will support development of the company's TRIMTAC and TRIMGLUE degrader platforms targeting conditions such as Alzheimer's disease, which affects over 55 million people globally.